- Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
- Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
- Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
- Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
- Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
- Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
- Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
- Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
More ▼
Key statistics
As of last trade Jazz Pharmaceuticals PLC (JAZZ:NSQ) traded at 106.97, 3.84% above its 52-week low of 103.01, set on May 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 107.65 |
---|---|
High | 107.87 |
Low | 106.41 |
Bid | 106.86 |
Offer | 107.01 |
Previous close | 108.08 |
Average volume | 881.24k |
---|---|
Shares outstanding | 63.06m |
Free float | 61.31m |
P/E (TTM) | 22.30 |
Market cap | 6.82bn USD |
EPS (TTM) | 4.85 USD |
Data delayed at least 15 minutes, as of Jun 26 2024 18:45 BST.
More ▼